Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Regulatory
124 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Apr 26, 2021 | ema |
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.accelerated | approved | Sep 5, 2011 | ema |
| Abiraterone | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) |
Data updated 5 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Olaparib | 56 | 56 | 0 |
| Cisplatin | 21 | 7 | 14 |
| Rucaparib | 21 | 21 | 0 |
| Enzalutamide | 20 | 8 | 12 |
| Carboplatin | 17 | 9 | 8 |
| Abiraterone | 14 | 3 | 11 |
| Paclitaxel | 13 | 6 | 7 |
| Talazoparib | 12 | 12 | 0 |
| Platinum Compound | 7 | 6 | 1 |
| Trastuzumab | 6 | 6 | 0 |
| Cetuximab | 5 | 3 | 2 |
| Palbociclib | 5 | 4 | 1 |
| Temsirolimus |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| approved |
| May 22, 2018 |
| openfda |
| Abiraterone Acetate | EU EMA | Malignant Prostate Neoplasm | Treatment of adult patients with prostate cancer. | approved | Apr 19, 2023 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Mylan is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Aug 20, 2021 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Krka is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. | approved | Jun 24, 2021 | ema |
| Abiraterone Acetate | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) | approved | May 22, 2018 | openfda |
| Apalutamide | EU EMA | Nonmetastatic Castration-Resistant Prostate Carcinoma | Erleada is indicated: in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). | approved | Jan 14, 2019 | ema |
| Apalutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 ) | approved | Feb 14, 2018 | openfda |
| Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor | EU EMA | Malignant Prostate Neoplasm | Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. | withdrawnsince May 6, 2015 | Sep 6, 2013 | ema |
| Bevacizumab | US FDA | Malignant Cervical Neoplasm | Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. | approved | Feb 26, 2004 | openfda |
| Bicalutamide | US FDA | Prostate Carcinoma | 1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. Bicalutamide tablets 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. (1) Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments. (1) | approved | Oct 4, 1995 | openfda |
| Cabazitaxel | EU EMA | Malignant Prostate Neoplasm | Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. | approved | Aug 28, 2020 | ema |
| Cabazitaxel | EU EMA | Malignant Prostate Neoplasm | Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. | approved | Mar 17, 2011 | ema |
| Cabazitaxel | US FDA | Castration-Resistant Prostate Carcinoma | JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 ) | approved | Jun 17, 2010 | openfda |
| Capivasertib | US FDA | Malignant Prostate Neoplasm | PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer that is PTEN-deficient as detected by an FDA-authorized test. | approved | Nov 16, 2023 | openfda |
| Carboplatin | US FDA | Ovarian Carcinoma | As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. | approved | Aug 8, 2025 | openfda |
| Carboplatin | US FDA | Ovarian Carcinoma | As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. | approved | Aug 8, 2025 | openfda |
| Cyclophosphamide | US FDA | Ovarian Adenocarcinoma | adenocarcinoma of the ovary | approved | Sep 12, 2023 | openfda |
| Dabrafenib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated | approved | Mar 16, 2023 | openfda |
| Dabrafenib | US FDA | Tumor-agnostic | the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated | approved | May 29, 2013 | openfda |
| Dactinomycin | US FDA | Malignant Testicular Neoplasm | adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. | approved | Nov 9, 2017 | openfda |
| Darolutamide | EU EMA | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1). | approved | Mar 27, 2020 | ema |
| Darolutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. | approved | Jul 30, 2019 | openfda |
| Degarelix | EU EMA | Malignant Prostate Neoplasm | Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated: for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer. | approved | Sep 29, 2023 | ema |
| Degarelix | EU EMA | Malignant Prostate Neoplasm | FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer. | approved | Feb 17, 2009 | ema |
| Degarelix | US FDA | Malignant Prostate Neoplasm | FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 ) | approved | Dec 24, 2008 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Oct 29, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Mar 25, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Feb 13, 2025 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. | approved | Mar 5, 2024 | openfda |
| Denosumab | US FDA | Malignant Prostate Neoplasm | to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer | approved | Jun 1, 2010 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Oct 23, 2024 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC | approved | Nov 22, 2022 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Apr 12, 2013 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Jun 29, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer | approved | Jun 8, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | May 3, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer | approved | Mar 8, 2011 | openfda |
| Docetaxel | US FDA | Castration-Resistant Prostate Carcinoma | Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer | approved | May 14, 1996 | openfda |
| Dostarlimab | EU EMA | Malignant Endometrial Neoplasm | Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen. | approved | Apr 21, 2021 | ema |
| Dostarlimab | US FDA | Malignant Endometrial Neoplasm | Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). | approved | Apr 22, 2021 | openfda |
| Dostarlimab | US FDA | Tumor-agnostic | as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. • Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 1 • 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated | approved | Apr 22, 2021 | openfda |
| Doxorubicin | US FDA | Malignant Ovarian Neoplasm | Ovarian cancer: After failure of platinum-based chemotherapy | approved | Nov 17, 1995 | openfda |
| Durvalumab | US FDA | Malignant Endometrial Neoplasm | in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test. | approved | May 1, 2017 | openfda |
| Entrectinib | EU EMA | Tumor-agnosticLung Non-Small Cell Carcinoma | Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional | approved | Jul 31, 2020 | ema |
| Entrectinib | US FDA | Tumor-agnostic | Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.accelerated | approved | Oct 20, 2023 | openfda |
| Entrectinib | US FDA | Tumor-agnostic | Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.accelerated | approved | Aug 15, 2019 | openfda |
| Enzalutamide | EU EMA | Castration-Resistant Prostate Carcinoma | Enzalutamide Viatris is indicated:• as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy (see section 5.1);• in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1); • for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1);• for the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1);• for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy. | approved | Aug 22, 2024 | ema |
| 5 |
| 4 |
| 1 |
| Dasatinib | 4 | 4 | 0 |
| Docetaxel | 4 | 3 | 1 |
| Doxorubicin | 4 | 2 | 2 |
| Trametinib | 4 | 4 | 0 |
| Afatinib | 3 | 3 | 0 |
| Bevacizumab | 3 | 2 | 1 |
| Bicalutamide | 3 | 0 | 3 |
| Cabazitaxel | 3 | 2 | 1 |
| Capivasertib | 3 | 2 | 1 |
| Dinaciclib | 3 | 3 | 0 |
| Linsitinib | 3 | 3 | 0 |
| Niraparib | 3 | 3 | 0 |
| Pembrolizumab | 3 | 3 | 0 |
| Pictilisib | 3 | 3 | 0 |
| Ridaforolimus | 3 | 2 | 1 |
| Abiraterone Acetate | 2 | 0 | 2 |
| Atezolizumab | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Cediranib | 2 | 2 | 0 |
| Decitabine | 2 | 2 | 0 |
| Dostarlimab | 2 | 2 | 0 |
| Eprenetapopt | 2 | 2 | 0 |
| Erdafitinib | 2 | 2 | 0 |
| Erlotinib | 2 | 1 | 1 |
| Everolimus | 2 | 2 | 0 |
| Imatinib | 2 | 2 | 0 |
| Ipatasertib | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Taxane Compound | 2 | 1 | 1 |
| Vemurafenib | 2 | 2 | 0 |
| Abemaciclib | 1 | 1 | 0 |
| Akt Inhibitor MK2206 | 1 | 1 | 0 |
| Alpelisib | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| Asparaginase | 1 | 0 | 1 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Binimetinib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| Carboplatin/Paclitaxel Regimen | 1 | 1 | 0 |
| CDK Inhibitor SNS-032 | 1 | 1 | 0 |
| Crizotinib | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Dabrafenib | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| Entrectinib | 1 | 0 | 1 |
| Etoposide | 1 | 0 | 1 |
| Fadraciclib | 1 | 1 | 0 |
| Fexagratinib | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| Fulvestrant | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| Immune Checkpoint Inhibitor | 1 | 1 | 0 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| Lonafarnib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 1 | 1 | 0 |
| Navtemadlin | 1 | 1 | 0 |
| Nilutamide | 1 | 0 | 1 |
| Nivolumab | 1 | 1 | 0 |
| Panitumumab | 1 | 0 | 1 |
| PD173074 | 1 | 1 | 0 |
| Pemetrexed | 1 | 1 | 0 |
| Pertuzumab | 1 | 1 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 1 | 1 | 0 |
| Picoplatin | 1 | 0 | 1 |
| Ponatinib | 1 | 1 | 0 |
| Prednisone | 1 | 1 | 0 |
| Ribociclib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| Selumetinib | 1 | 1 | 0 |
| Seribantumab | 1 | 1 | 0 |
| Taselisib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Veliparib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.